Cargando…
Active Postlicensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record Data
Recombinant zoster vaccine (RZV) (Shingrix; GlaxoSmithKline, Brentford, United Kingdom) is an adjuvanted glycoprotein vaccine that was licensed in 2017 to prevent herpes zoster (shingles) and its complications in older adults. In this prospective, postlicensure Vaccine Safety Datalink study using el...
Autores principales: | Nelson, Jennifer C, Ulloa-Pérez, Ernesto, Yu, Onchee, Cook, Andrea J, Jackson, Michael L, Belongia, Edward A, Daley, Matthew F, Harpaz, Rafael, Kharbanda, Elyse O, Klein, Nicola P, Naleway, Allison L, Tseng, Hung-Fu, Weintraub, Eric S, Duffy, Jonathan, Yih, W Katherine, Jackson, Lisa A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896469/ https://www.ncbi.nlm.nih.gov/pubmed/36193854 http://dx.doi.org/10.1093/aje/kwac170 |
Ejemplares similares
-
Postlicensure herpes zoster vaccine effectiveness: systematic review protocol
por: Mbinta, James F, et al.
Publicado: (2021) -
Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018
por: Hesse, Elisabeth M., et al.
Publicado: (2019) -
2767. Variation in Incidence of Pediatric Herpes Zoster by First- and Second-Dose Varicella Vaccine Formulations
por: Weinmann, Sheila, et al.
Publicado: (2019) -
Detection of Novel Rotavirus Strain by Vaccine Postlicensure Surveillance
por: Weinberg, Geoffrey A., et al.
Publicado: (2013) -
Licensing Examination and Crash Outcomes Postlicensure in Young Drivers
por: Walshe, Elizabeth A., et al.
Publicado: (2022)